共 368 条
[1]
Douillard JY(2000)Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 1041-1047
[2]
Cunningham D(2000)Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 905-914
[3]
Roth AD(2007)Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool Clin Colorectal Cancer 6 367-373
[4]
Navarro M(2013)Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey Jpn J Clin Oncol 43 483-491
[5]
James RD(2000)Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Cancer Res 60 6921-6926
[6]
Karasek P(2011)Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms Jpn J Clin Oncol 41 477-482
[7]
Jandik P(2006)The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer J Clin Oncol 24 3061-3068
[8]
Iveson T(2009)Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan J Clin Oncol 27 2457-2465
[9]
Carmichael J(2013)Polymorphisms of the UDP-glucuronosyl transferase 1A Genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy Tohoku J Exp Med 229 107-114
[10]
Alakl M(2002)UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity Pharmacogenomics J 2 43-47